Kiromic Biopharma Inc Cash Flow-to-Debt Ratio
Kiromic Biopharma Inc cash flow-to-debt ratio. Kiromic Biopharma Inc (KRBP) has a Cash Flow-to-Debt Ratio of -0.17x as of December 2024, meaning its operating cash flow of $-3.65 Million could theoretically repay 0% of its total liabilities ($21.13 Million) in one year. See financial flexibility index of Kiromic Biopharma Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kiromic Biopharma Inc (2018–2024)
Cash flow-to-debt ratio of Kiromic Biopharma Inc from 2018 to 2024. Historical debt coverage capacity for Kiromic Biopharma Inc across 7 annual periods. Also explore KRBP shareholders equity momentum to track the company's year-over-year net asset growth rate.
Kiromic Biopharma Inc Cash Flow-to-Debt Ratio by Year (2018–2024)
Kiromic Biopharma Inc cash flow-to-debt ratio by year from 2018 to 2024. Year-by-year debt coverage analysis for Kiromic Biopharma Inc. For the full cash flow conversion analysis, see Kiromic Biopharma Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.92x | $-19.46 Million | $21.13 Million | ▲ +7.6% |
| 2023 | -1.00x | $-21.23 Million | $21.29 Million | ▲ +25.5% |
| 2022 | -1.34x | $-23.75 Million | $17.74 Million | ▲ +77.5% |
| 2021 | -5.96x | $-20.32 Million | $3.41 Million | ▼ -42.8% |
| 2020 | -4.17x | $-6.13 Million | $1.47 Million | ▲ +3.5% |
| 2019 | -4.33x | $-2.91 Million | $673.70K | ▼ -22.7% |
| 2018 | -3.53x | $-2.15 Million | $610.70K | — |